cmAngio® vs Imbio PHA (4.0.0)
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A focuses on detecting breast arterial calcifications from mammograms for cardiovascular risk assessment in women. Tool B, conversely, analyzes CT pulmonary angiogram scans to measure cardiac structures for diagnosing and stratifying risk in pulmonary embolism and hypertension. While both are FDA-cleared AI tools in cardiology and radiology, they address distinct clinical questions using different imaging modalities, making them adjacent rather than direct competitors.
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography data for early cardiovascular risk assessment in women. This tool is ideal for integrating a proactive cardiovascular health screening into routine breast cancer screening workflows, identifying potential risks without additional procedures or radiation exposure.
View cmAngio® →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if you need automated, rapid assessment of cardiac structures from CT pulmonary angiogram (CTPA) scans for patients with suspected or diagnosed pulmonary embolism or hypertension. This software is best suited for quickly quantifying right ventricular dilation and other key cardiac measurements to aid in acute diagnosis and risk stratification.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Imbio PHA (4.0.0) |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Imbio PHA (4.0.0) |
|---|---|---|
| Name | cmAngiou00ae | Imbio PHA (4.0.0) |
| Company | CureMetrix | Imbio |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | Automated measurement of right and left ventricle diameters |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Automated measurement of main pulmonary artery and aorta diameters |
| Key Feature 3 | Provides visualization of BAC location on a scorecard | Calculates RV/LV and PA/Ao ratios |
| Primary Clinical Focus | Breast Arterial Calcifications (BAC) detection on mammograms for cardiovascular health assessment | Cardiac structure measurement from CTPA scans for pulmonary embolism and hypertension assessment |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Imbio PHA (4.0.0).
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
cmAngiou00ae by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. Imbio PHA (4.0.0) is an FDA-cleared AI-powered software that measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. Imbio PHA (4.0.0) processes CT pulmonary angiogram (CTPA) scans.
cmAngiou00ae provides visualization of BAC location on a scorecard and enables BAC identification and reporting without additional radiation or procedures. Imbio PHA (4.0.0) generates automated measurements of right and left ventricle diameters, main pulmonary artery and aorta diameters, calculates RV/LV and PA/Ao ratios, and provides annotated DICOM images and summary reports in PDF format.
cmAngiou00ae uses AI for the detection and localization of Breast Arterial Calcifications (BAC). Imbio PHA (4.0.0) utilizes artificial intelligence algorithms for anatomical identification and measurement of cardiac structures, specifically focusing on right and left ventricle diameters, main pulmonary artery and aorta diameters, and their respective ratios.
cmAngiou00ae is compatible with any DICOM-compliant viewer and is designed for quick and easy installation, typically in less than an hour. Imbio PHA (4.0.0) integrates with native DICOM tools and workflows, providing rapid, fully-automated assessments, typically in minutes.